@abcuro.com
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Abcuro is a groundbreaking brand that specializes in developing breakthrough therapies for autoimmune diseases and cancer. Their lead product candidate, ABC008, is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells in autoimmune disorders. By targeting the killer cell lectin-like receptor G1 (KLRG1), which is selectively expressed on these cells, ABC008 aims to address the chronic tissue damage caused by cytotoxic T cells in conditions like inclusion body myositis (IBM).
In a recent Phase 1 open-label trial, ABC008 demonstrated potent depletion of KLRG1+ T cells in patients with IBM, showing promising results. Additionally, Abcuro is advancing ABC015, a KLRG1-blocking antibody, for immune-oncology applications. With a team of experienced leaders and a strong pipeline including other indications, Abcuro is dedicated to making a significant impact in the field of autoimmune diseases and cancer treatment
Company Type
Privately Held
Company Size
2-10
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories